AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
NCT01741194
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
418
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
DRUG:
AC-1204
DRUG:
Placebo
Sponsor
Cerecin